Subcutaneous neostigmine – a safe alternative in acute colonic pseudo-obstruction.
C. J GILLESPIE, M. von Papen, C.T. Lu
Purpose: Intravenous neostigmine is a well established treatment for acute colonic pseudo-obstruction. Its use is hampered by the requirement for cardiac monitoring and patients are often transferred to high dependency units for close observation during treatment. Subcutaneous neostigmine has the potential to minimise adverse cardiovascular effects whilst maintaining efficacy and has been described in patients with myasthenia gravis. This study aims to assess the safety and success of subcutaneous neostigmine on ward inpatients with acute colonic pseudo-obstruction monitored with standard nursing care.
Methods: A prospective series of 30 patients treated for acute colonic pseudo-obstruction with subcutaneous neostigmine were collected between August 2008 and October 2012. All patients were diagnosed using clinical examination and radiology and were assessed for contraindications to neostigmine. Patients were treated on regular wards and monitored with standard nursing observations. Data collected included time to flatus and bowels working, demographics, clinical scenario, comorbidities, medications, electrolyte derangements and complications.
Results: 93% of patients had clinically successful resolution of acute colonic pseudo-obstruction. Two patients (7%) failed subcutaneous neostigmine and required colonoscopic decompression, which was successful in both instances. The mean time to bowels opening was 29 hours. No complications were encountered.
Conclusion: Subcutaneous neostigmine is a safe and effective treatment for acute colonic pseudo-obstruction. It can be used on a regular ward and may obviate the need for transfer of these patients for cardiac monitoring.
Presenting Author Biography
Chris Gillespie is a 2nd year colorectal fellow currently based at the Gold Coast Hospital. Originally a kiwi, Chris did his general surgical training at St. Vincent’s Hospital in Melbourne before being accepted to the CSSANZ colorectal fellowship programme.